


ALERT 
**TO**

Hospital Providers, HMOs and Other Managed Care Programs

REGARDING

New Procedure Codes in Response to COVID-19

New Procedure Codes in Response to COVID-19

In response to the COVID-19 pandemic, the Centers for Medicare & Medicaid Services has implemented 12 new procedure codes to describe the introduction or infusion of therapeutics and convalescent plasma.

For dates of service on and after August 1, 2020, ForwardHealth will accept and process inpatient hospital claims with the following International Classification of Diseases, 10th Revision, Procedure Coding System codes without prior authorization when they are administered in accordance with current Food and Drug Administration guidance.

ICD CODE	CODE DESCRIPTION
XW013F5	Introduction of other new technology therapeutic substance into subcutaneous tissue, percutaneous approach, new technology group 5
XW033E5	Introduction of remdesivir anti-infective into peripheral vein, percutaneous approach, new technology group 5
XW033F5	Introduction of other new technology therapeutic substance into peripheral vein, percutaneous approach, new technology group 5
XW033G5	Introduction of sarilumab into peripheral vein, percutaneous approach, new technology group 5
XW033H5	Introduction of tocilizumab into peripheral vein, percutaneous approach, new technology group 5
XW043E5	Introduction of remdesivir anti-infective into central vein, percutaneous approach, new technology group 5

ICD CODE	CODE DESCRIPTION
XW043F5	Introduction of other new technology therapeutic substance into central vein, percutaneous approach, new technology group 5
XW043G5	Introduction of sarilumab into central vein, percutaneous approach, new technology group 5
XW043H5	Introduction of tocilizumab into central vein, percutaneous approach, new technology group 5
XW0DXF5	Introduction of other new technology therapeutic substance into mouth and pharynx, external approach, new technology group 5
XW13325	Transfusion of convalescent plasma (nonautologous) into peripheral vein, percutaneous approach, new technology group 5
XW14325	Transfusion of convalescent plasma (nonautologous) into central vein, percutaneous approach, new technology group 5